Exscientia

Company profile

About Exscientia

Recursion is a pioneering TechBio company founded over a decade ago on the revolutionary idea of using cellular imaging and artificial intelligence to decode biology and transform drug discovery. The company has built the Recursion Operating System (Recursion OS), an advanced AI-driven drug discovery and development platform that leverages one of the largest fit-for-purpose proprietary biological and chemical datasets in the world—over 50 petabytes spanning phenomics, transcriptomics, proteomics, ADME, and de-identified patient data. Recursion's mission is to radically improve lives by addressing the massive 90% failure rate of traditional drug discovery through novel insights and precision design. The company's automated wet lab utilizes robotics and computer vision to capture millions of cell experiments per week, feeding results back into the platform in a continuously improving feedback loop. This approach has demonstrated significant improvements in speed, efficiency, and reduced costs from hit identification to IND-enabling studies compared to traditional pharmaceutical company averages. The company has developed an advanced pipeline of potential first-in-class and best-in-class treatments targeting conditions with high unmet need, including aggressive cancers such as advanced solid tumors, B-cell malignancies, and lymphomas, as well as rare diseases like familial adenomatous polyposis and hypophosphatasia. Multiple programs are currently in clinical trials, including the TUPELO, ELUCIDATE, DAHLIA, EXCELERIZE, and ENLYGHT studies. Recursion partners with pharmaceutical industry leaders and technology giants like NVIDIA, with whom they built BioHive-2, biopharma's most powerful supercomputer. The company is headquartered in Salt Lake City, Utah, and is a proud founding member of BioHive, the fastest-growing life sciences community in the nation.

Company description · Exscientia official website